论文部分内容阅读
目的:探讨血浆一氧化氮(NO)水平在酒精性心肌病(ACM)患者疗效评估中的作用。方法:纳入32例ACM患者,给予戒酒和心力衰竭的标准治疗,治疗前和治疗3个月后行超声心动图检查评估左室舒张末期内径(LVEDD)和左室射血分数(LVEF),检测血浆NO水平。比较治疗前后NO的水平,并将NO水平的变化幅度与治疗后LVEDD和LVEF的变化幅度进行相关性分析。结果:治疗3个月后血浆NO的水平显著高于治疗前的水平(22.86±6.61μmol/L vs.26.23±6.52μmol/L,P<0.01)。治疗3个月后血浆NO水平的增加幅度与LVEDD的降低幅度(r=0.78,95%CI:0.60～0.89,P<0.01)和LVEF的升高幅度(r=0.75,95%CI:0.55～0.87,P<0.01)均显著相关。结论:血浆NO水平的变化可用于评估ACM患者的疗效。
Objective: To investigate the role of plasma nitric oxide (NO) level in evaluating the curative effect of alcoholic cardiomyopathy (ACM). Methods: Thirty-two patients with ACM were enrolled in this study. Standard treatment of abstinence and heart failure were included. Left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were assessed by echocardiography before treatment and 3 months after treatment. Plasma NO levels were measured. The levels of NO before and after treatment were compared, and the correlation between the change of NO level and the changes of LVEDD and LVEF after treatment were analyzed. Results: After 3 months of treatment, the level of plasma NO was significantly higher than that before treatment (22.86 ± 6.61μmol / L vs.26.23 ± 6.52μmol / L, P <0.01). After 3 months of treatment, the increase of plasma NO and the decrease of LVEDD (r = 0.78,95% CI: 0.60-0.89, P <0.01) and LVEF increased (r = 0.75,95% CI: 0.87, P <0.01) were significantly correlated. Conclusion: Changes in plasma NO levels can be used to assess the efficacy of ACM patients.